Immediate Impact
1 from Science/Nature 72 standout
Citing Papers
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Works of Sarah E. Taylor being referenced
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Sarah E. Taylor | 157 | 194 | 132 | 144 | 62 | 497 | |
| Mustafa Zelal Muallem | 266 | 254 | 108 | 185 | 56 | 530 | |
| Norman G. Rosenblum | 244 | 168 | 98 | 117 | 43 | 547 | |
| Margherita Fischetti | 260 | 233 | 122 | 177 | 39 | 559 | |
| Summer Dewdney | 162 | 183 | 103 | 121 | 35 | 435 | |
| Christine Brambs | 145 | 212 | 92 | 98 | 59 | 474 | |
| Kelly J. Manahan | 164 | 231 | 107 | 181 | 45 | 548 | |
| Krzysztof Urbański | 103 | 144 | 129 | 109 | 49 | 554 | |
| Rafał Watrowski | 152 | 131 | 144 | 93 | 53 | 575 | |
| Nathaniel Jones | 155 | 159 | 192 | 67 | 43 | 504 | |
| Jason Yap | 231 | 290 | 84 | 107 | 33 | 497 |
All Works
Login with ORCID to disown or claim papers
Loading papers...